Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "Binge-Eating Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Binge-Eating Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-Eating Disorder pipeline landscape is provided which includes the disease overview and Binge-Eating Disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-Eating Disorder commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-Eating Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Binge-Eating Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-Eating Disorder.
Binge-Eating Disorder Emerging Drugs Chapters
This segment of the Binge-Eating Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Binge-Eating Disorder Emerging Drugs
TRP-8803: Tryp Therapeutics
TRP-8803 is a proprietary formulation of IV-infused psilocin, addressing the drawbacks of oral psilocybin. It provides faster onset times, better control over the psychedelic experience, and reduced treatment durations compared to traditional methods. Currently undergoing clinical trials for binge eating disorder and fibromyalgia, it shows promising results as a safer and more effective alternative to existing treatments. It is in Phase II stage of its clinical trial.
Major Players in Binge-Eating Disorder
There are approx. 3+ key companies which are developing the therapies for Binge-Eating Disorder. The companies which have their Binge-Eating Disorder drug candidates in the most advanced stage, i.e. Phase II include, Tryp Therapeutics.
Binge-Eating Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Binge-Eating Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-Eating Disorder drugs.
Key Questions
- How many companies are developing Binge-Eating Disorder drugs?
- How many Binge-Eating Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Binge-Eating Disorder?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Binge-Eating Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Binge-Eating Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- TRYP Therapeutics
- Tonix Pharmaceuticals
Key Products
- TRYP-0082
- Oxytocin
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Binge-Eating Disorder Report Insights
- Binge-Eating Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Binge-Eating Disorder Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ib09hm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
